AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 28825235
Drug: Placebo aerosol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo aerosol spray (n=60)
Trial: 26074365
Drug: Platelet-rich plasma
RxNorm normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet-rich plasma (PRP) administered through a buccal window approach
Trial: 26074365
Drug: Conventional management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional management via creation of a window on the buccal wall and curettage of the walls of the defect
Trial: 25309087
Drug: Aconite cake‐separated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aconite cake‐separated moxibustion (1 cone, 3 treatments/week)
Trial: 25309087
Drug: Aconite cake‐separated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aconite cake‐separated moxibustion (2 cones, 3 treatments/week)
Trial: 25309087
Drug: Aconite cake‐separated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aconite cake‐separated moxibustion (1 cone, 6 treatments/week)
Trial: 25309087
Drug: Aconite cake‐separated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aconite cake‐separated moxibustion (2 cones, 6 treatments/week)
Trial: 21247664
Drug: Biafine Topical
RxNorm normalized name: Biafine Topical Emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biafine Topical Emulsion (BTE)
Trial: 15117996
Drug: Acupuncture twice
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture twice per week for 4 weeks
Trial: 3475231
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg or 2 mg PGE2 intravaginally at an interval of 6 hours
Trial: 3475231
Drug: Intravenous oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous oxytocin and amniotomy
Trial: 2129320
Drug: pravastatin 20
RxNorm normalized name: pravastatin 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pravastatin 20 mg b.i.d.
Trial: 2129320
Drug: cholestyramine 16‐24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cholestyramine 16‐24 g/day
Trial: 973981
Drug: Diazepam (5-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (5-10 mg three times daily)
Trial: 973981
Drug: Thioridazine (25-50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thioridazine (25-50 mg three times daily)
Trial: 27842179
Drug: Sacubitril/Valsartan 97/103
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sacubitril/Valsartan 97/103 mg twice daily
Trial: 27842179
Drug: Sacubitril/Valsartan 97/103
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sacubitril/Valsartan 97/103 mg twice daily (newly started MRA)
Trial: 27842179
Drug: Enalapril 10
RxNorm normalized name: enalapril 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 10 mg twice daily (newly started MRA)
Trial: 26291258
Drug: Triamcinolone hexacetonide
RxNorm normalized name: Triamcinolone Hexacetonide
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triamcinolone hexacetonide (20mg/ml)
Trial: 21784746
Drug: Standard arrhythmia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard arrhythmia detection and therapy approaches (Control group)
Trial: 16565252
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human erythropoietin (EPO) treatment to normalize hemoglobin (Hgb) levels.
Trial: 16565252
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human erythropoietin (EPO) treatment to achieve Hgb >12 g/dl.
Trial: 16565252
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human erythropoietin (EPO) treatment to achieve Hgb >11 g/dl.
Trial: 16565252
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human erythropoietin (EPO) treatment for normalization of hematocrit.
Trial: 16565252
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human erythropoietin (EPO) treatment.
Trial: 3774016
Drug: Adjuvant combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant combination chemotherapy with low-dose prednisone (7.5 mg/day) and CMF (cyclophosphamide, methotrexate, and 5-fluorouracil)
Trial: 3774016
Drug: CMFp +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMFp + T (chemotherapy plus low-dose prednisone and tamoxifen)
Trial: 3774016
Drug: Endocrine therapy
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endocrine therapy alone (p + T)
Trial: 3774016
Drug: No further
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No further treatment after total mastectomy and axillary clearance (observation group)
Trial: 28815256
Drug: Ibuprofen capsules
RxNorm normalized name: Diphenhydramine Hydrochloride and Ibuprofen Capsules
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen capsules
Trial: 25661407
Drug: Children with
RxNorm normalized name: Pediaclear Childrens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Children with high Lp(a) concentrations (>500 mg/L) in the intervention group
Trial: 18204335
Drug: Aripiprazole (initiated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole (initiated at 10 mg/d, flexibly dosed at 5-30 mg/d)
Trial: 16728480
Drug: Concurrent radiochemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent radiochemotherapy (RT-CT) - two cycles of platinum etoposide followed by two cycles of platinum-vinorelbine
Trial: 16728480
Drug: Sequential radiochemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential radiochemotherapy (RT-CT) - three cycles of chemotherapy followed by radiotherapy
Trial: 9892032
Drug: HFA-134a albuterol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HFA-134a albuterol sulfate (108 microg of albuterol sulfate, equivalent to 90 microg of albuterol base)
Trial: 9892032
Drug: CFC albuterol
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CFC albuterol (equivalent doses)
Trial: 2363736
Drug: Low-dose fish
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose fish oil (27 mg/kg EPA and 18 mg/kg DHA)
Trial: 2363736
Drug: High-dose fish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose fish oil (54 mg/kg EPA and 36 mg/kg DHA)
Trial: 2363736
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (low-dose, high-dose, and olive oil)
Trial: 26725184
Drug: Erlotinib (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib (150 mg orally daily on days 2-16) plus Carboplatin (AUC=5 on day 1) and Paclitaxel (200 mg/m2 intravenously on day 1) followed by Erlotinib (150 mg orally)
Trial: 25332253
Drug: Proton radiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton radiotherapy with chemotherapy (vincristine, actinomycin, and cyclophosphamide or vincristine, actinomycin, and ifosfamide)
Trial: 25332253
Drug: Proton radiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton radiotherapy with chemotherapy
Trial: 12003920
Drug: Non-at-risk drinkers
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-at-risk drinkers in occupational medicine vs. primary care
Trial: 12003920
Drug: At-risk drinkers
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At-risk drinkers in occupational medicine vs. primary care
Trial: 7886126
Drug: Erythromycin estolate
RxNorm normalized name: Erythromycin Estolate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin estolate (1000 mg twice daily)
Trial: 7886126
Drug: Erythromycin ethylsuccinate
RxNorm normalized name: Erythromycin Ethylsuccinate
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erythromycin ethylsuccinate (1500 mg daily, 50% higher than erythromycin estolate)
Trial: 2219563
Drug: EMLA cream
RxNorm normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EMLA cream (lidocaine-prilocaine), applied for 60 minutes
Trial: 2219563
Drug: EMLA cream
RxNorm normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EMLA cream (lidocaine-prilocaine), applied for over 90 minutes
Trial: 26044714
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of touch and vision
Trial: 24522442
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg DHA/d (treatment)
Trial: 15182773
Drug: Carvedilol (target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol (target 25 mg bid)
Trial: 15182773
Drug: Enalapril (target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (target 10 mg bid)
Trial: 15182773
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of carvedilol and enalapril
Trial: 15182773
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (combination, carvedilol, enalapril)
Trial: 1907432
Drug: 20 infusions
RxNorm normalized name: nitroglycerin
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 infusions of Na2EDTA
Trial: 1907432
Drug: 20 infusions
RxNorm normalized name: nitroglycerin
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 infusions of saline
Trial: 6135253
Drug: Beta-blockade maintained
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blockade maintained with 100 mg metoprolol per os two hours before surgery
Trial: 27122150
Drug: Retinyl palmitate
RxNorm normalized name: Retinyl palmitate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retinyl palmitate supplementation (25,000 IU daily)
Trial: 15730048
Drug: Dipyridamole 5
RxNorm normalized name: dipyridamole 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipyridamole 5 mg/kg
Trial: 12517683
Drug: GRD 360
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GRD 360 mg administered once-daily at bedtime (10 PM)
Trial: 12517683
Drug: GRD 240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GRD 240 mg and higher administered once-daily at bedtime
Trial: 12517683
Drug: All GRD
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All GRD groups (including 540 mg and 240 mg)
Trial: 12517683
Drug: GRD 540
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GRD 540 mg administered once-daily at bedtime
Trial: 12517683
Drug: GRD 360
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GRD 360 mg administered once-daily at 8 AM
Trial: 9402265
Drug: Continuation of
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuation of daily GnRHa injections for 15 days after HCG administration
Trial: 9402265
Drug: Disruption of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disruption of daily GnRHa injections at the day of HCG administration
Trial: 8228208
Drug: Lisinopril (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril (10 mg once a day)
Trial: 8228208
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of amlodipine and lisinopril (once a day)
Trial: 3943269
Drug: Nalmefene 6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalmefene 6 mg
Trial: 3943269
Drug: Nalmefene 12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalmefene 12 mg
Trial: 3943269
Drug: Nalmefene 24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalmefene 24 mg
Trial: 3943269
Drug: Nalmefene (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalmefene (all doses)
Trial: 26558919
Drug: Urinary iodine
RxNorm normalized name: Iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Urinary iodine excretion
Trial: 16077402
Drug: High tidal
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High tidal volume/low positive end-expiratory pressure (10-12 mL/kg and 2-3 cm H2O)
Trial: 16077402
Drug: Low tidal
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low tidal volume/high positive end-expiratory pressure (8 mL/kg and 10 cm H2O)
Trial: 8745670
Drug: Granisetron (G)
RxNorm normalized name: Granisetron
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Granisetron (G) 3 mg intravenously before chemotherapy
Trial: 8745670
Drug: Ondansetron (O)
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ondansetron (O) 8 mg intravenously, followed by 8 mg orally every eight hours for the next three days
Trial: 6753090
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg naproxen administered as a single dose at night
Trial: 6753090
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg naproxen administered twice daily
Trial: 23574579
Drug: LMWH followed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: LMWH followed by warfarin (INR of 2.0-3.0)
Trial: 21507585
Drug: Nicotine patch
RxNorm normalized name: Nicotine Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine patch plus bupropion
Trial: 19585106
Drug: Citalopram (selective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (selective serotonin reuptake inhibitor) for 7-10 days
Trial: 17763613
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment with fractional resurfacing and ALA-PDT
Trial: 14994406
Drug: 5% ibuprofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% ibuprofen cream applied in a 10-cm strip tid for 7 days (approximately 200 mg ibuprofen per strip)
Trial: 14994406
Drug: 5% ibuprofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% ibuprofen cream
Trial: 9481194
Drug: Intrapartum amnioinfusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrapartum amnioinfusion (AI) with 0.9% normal saline at 15 ml/min until a volume of 11 was completed, repeated if delivery did not occur within 4 hours.
Trial: 7993831
Drug: granisetron 1
RxNorm normalized name: granisetron 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: granisetron 1 mg bd orally for 7 days
Trial: 7993831
Drug: granisetron 1
RxNorm normalized name: granisetron 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: granisetron 1 mg bd orally for 7 days plus prophylactic dexamethasone (12 mg i.v.) on the first day only
Trial: 7993831
Drug: metoclopramide (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metoclopramide (3 mg/kg i.v. loading dose; 4 mg/kg i.v. infusion) plus dex (12 mg i.v.) on the first day followed by met 10 mg orally tds for a further 6 days
Trial: 2544431
Drug: Itraconazole capsules
RxNorm normalized name: Itraconazole Capsules
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Itraconazole capsules (50 mg)
Trial: 2544431
Drug: Itraconazole capsules
RxNorm normalized name: Itraconazole Capsules
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Itraconazole capsules (100 mg)
Trial: 2544431
Drug: Itraconazole capsules
RxNorm normalized name: Itraconazole Capsules
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Itraconazole capsules (200 mg)
Trial: 2544431
Drug: Itraconazole capsules
RxNorm normalized name: Itraconazole Capsules
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Itraconazole capsules (100 mg) after 15 days
Trial: 29664999
Drug: Fibrin sealant
RxNorm normalized name: FIBRIN SEALANT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrin sealant patch (patch group)
Trial: 29664999
Drug: No patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No patch (control group)
Trial: 26141683
Drug: FOLFIRI-cetuximab followed
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: FOLFIRI-cetuximab followed by oxaliplatin-based second-line chemotherapy with bevacizumab (Arm A)
Trial: 26141683
Drug: OPTIMOX-bevacizumab followed
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: OPTIMOX-bevacizumab followed by irinotecan-based second-line chemotherapy with bevacizumab and anti-EGFR monoclonal antibody (Arm B)
Trial: 21139151
Drug: Candidate vaginal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candidate vaginal microbicide gel containing cellulose acetate 1,2‐benzenedicarboxylate in a glycerol‐based vehicle
Trial: 21139151
Drug: Candidate vaginal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candidate vaginal microbicide gel
Trial: 16832124
Drug: Co-amoxiclav (antibiotics)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-amoxiclav (antibiotics) administered on the day before and the day of embryo transfer
Trial: 8900553
Drug: Methotrexate (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate (50 mg per m2) + Misoprostol (800 micrograms)
Trial: 8900553
Drug: Misoprostol (vaginal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Misoprostol (vaginal administration)
Trial: 1797509
Drug: Insulin and
RxNorm normalized name: Isophane insulin and porcine regular insulin only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin and Glyburide (IG)
Trial: 1797509
Drug: Insulin and
RxNorm normalized name: Isophane insulin and porcine regular insulin only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin and Placebo (IP)
Trial: 21390173
Drug: Adenosine (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adenosine (80 µg/kg/min)
Trial: 19433134
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (combined mechanical vibrations, continuous passive motion, and thermotherapy)
Trial: 15471073
Drug: GnRHa therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GnRHa therapy with 15 microg of diluted buserelin acetate given once a day intranasally
Trial: 15471073
Drug: Clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate 50 mg daily by oral administration
Trial: 11327741
Drug: Long-chain triglycerides
RxNorm normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-chain triglycerides (LCTs) infusion
Trial: 1064903
Drug: Liquid antacid
RxNorm normalized name: GNP Liquid Antacid Maximum Strength 400mg-400mg-40mg/5ml Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid antacid co-administered with ferrous salts (carbonate, fumarate, sulphate)
Trial: 1064903
Drug: Ferrous carbonate
RxNorm normalized name: ferrous carbonate
DrugBank: Ferrous carbonate (DB13698)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ferrous carbonate with liquid antacid
Trial: 29049382
Drug: Phone-based unannounced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phone-based unannounced pill counts in START (Lesotho)
Trial: 29049382
Drug: Phone-based unannounced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phone-based unannounced pill counts in ENRICH (Ethiopia)
Trial: 24063098
Drug: Alfaxalone 5
RxNorm normalized name: alfaxalone
DrugBank: Alfaxalone (DB11371)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfaxalone 5 mg/kg
Trial: 24063098
Drug: Alfaxalone 10
RxNorm normalized name: alfaxalone 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfaxalone 10 mg/kg
Trial: 24063098
Drug: Alfaxalone 15
RxNorm normalized name: alfaxalone
DrugBank: Alfaxalone (DB11371)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfaxalone 15 mg/kg
Trial: 24063098
Drug: Alfaxalone 100
RxNorm normalized name: alfaxalone
DrugBank: Alfaxalone (DB11371)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfaxalone 100 mg/kg
Trial: 15160265
Drug: Fluoxetine at
RxNorm normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine at 20 mg/day for 12 weeks
Trial: 11606923
Drug: 0.75% metronidazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75% metronidazole cream
Trial: 11606923
Drug: 1.0% metronidazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0% metronidazole cream
Trial: 7977476
Drug: On-line ST-segment
RxNorm normalized name: ST-36
DrugBank: ST-36 (DB17275)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On-line ST-segment monitoring with sestamibi injection
Trial: 238548
Drug: Lorazepam 3
RxNorm normalized name: lorazepam 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam 3 mg
Trial: 238548
Drug: Lorazepam 5
RxNorm normalized name: Lorazepam 500 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam 5 mg